Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire/Noven Daytrana Patch To Carry Similar Warnings To Other ADHD Drugs, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The transdermal methylphenidate patch is approved with one additional warning relating to skin reactions and possible sensitivity to oral methylphenidate products.

You may also be interested in...



Shire Voluntarily Withdraws Daytrana Patches After Enhancing Adhesive

Firm’s decision comes after patients and caregivers experienced difficulty removing the release liner from some Daytrana patches.

Shire Voluntarily Withdraws Daytrana Patches After Enhancing Adhesive

Firm’s decision comes after patients and caregivers experienced difficulty removing the release liner from some Daytrana patches.

A Sticky Situation For Shire’s Daytrana Patch, ISMP Reports

Shire will address adhesion issue following complaints that the adhesive for the patches sticks to the protective lining.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel